Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04375605

Recruitment Status : Recruiting

First Posted : May 5, 2020

Last Update Posted : July 6, 2022

See Contacts and Locations

Sponsor:

Collaborators:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Deutsche Krebshilfe e.V., Bonn (Germany)

Information provided by (Responsible Party):

Ralf Hofheinz, Universitätsmedizin Mannheim

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	May 2028
Estimated Study Completion Date :	August 2028

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer. 2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.

To Top